New program pairs microdoses of GLP-1 medication with Noom’s powerful behavior-change program and at-home biomarker testing to track the health impact of combining GLP-1 therapy with healthy habits.

SALT LAKE CITY, Dec. 17, 2025 /PRNewswire/ -- Shed, the wellness brand known for health and weight-loss solutions, has launched three new products to support long-term health: Tirzepatide Microdose ...

The two companies announced today that Hims & Hers will now be able to sell Novo Nordisk's injectable and oral semaglutide products, sold respectively as Ozempic for type 2 diabetes and Wegovy for ...

At-home health testing platform Ash is expanding its partnership with weight-loss company Noom to bring Noom's Proactive Health Microdose GLP-1Rx Program to market. Noom's program, launched in August, ...

Medical researchers are studying how GLP-1s could help treat menopause symptoms. Registered nurse Jacquie Anderson started microdosing these medications when her rigorous routines failed to maintain ...

While compounding pharmacies have played an outsize role in the rise of GLP-1 microdosing, questions remain about the quality and legality of what they’re selling. Are healthy guys who microdose ...

(Bloomberg) -- Weight-loss drugs are coming for a new kind of customer. “You don’t need to be obese to start a GLP-1,” reads an ad from a telehealth startup, the words scrawled in icing on a cake.

GLP-1 drugs may help boost heart attack recovery by lowering the risk of major complications, an animal study suggests.

Telehealth company Hims & Hers unleashed a wild few days in the obesity drug market when it introduced a cheap, compounded version of Novo Nordisk’s new Wegovy pill.

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve ...

GLP-1 medications mimic a natural hormone that controls appetite, blood sugar, and digestion. Monthly costs range from $199 to over $1,300, depending on the specific medication and insurance coverage.

The MarketWatch News Department was not involved in the creation of this content. New program pairs microdoses of GLP-1 medication with Noom's powerful behavior-change program and at-home biomarker ...